Transactions
4
Insider / AbbVie Inc.
WADDELL FREDERICK H
Director at AbbVie Inc.
- Company
- AbbVie Inc.
- First filing on record
- October 1, 2025
- Latest trade on record
- May 8, 2026
- SEC filings
- EDGAR ↗
WADDELL FREDERICK H, Director at AbbVie Inc., has disclosed 4 transactions in ABBV, IBM since October 1, 2025: 0 purchases (0 open-market buys) and 0 sales, worth about $293K at the reported prices. The latest was filed May 12, 2026, 4 days after the trade.
Open-market buys
0
Sales
0
Avg. disclosure lag
2.0d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months WADDELL FREDERICK H reported 3 transactions that were neither a purchase nor a sale, such as stock awards, option exercises or shares withheld for tax.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 4 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| A | Grant or award | 4 | 2,197 | $293K |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 2 | 0 | 0 |
| 2025 | 2 | 0 | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| ABBV | Other A | May 8, 2026 | May 12, 2026 | 4d | 1,118 | — | — | Form 4 ↗ | ||
| IBM | Other A | March 31, 2026 | April 1, 2026 | 1d | 403 | $242 | $98K | derivative | Form 4 ↗ | |
| IBM | Other A | December 31, 2025 | January 2, 2026 | 2d | 330 | $296 | $98K | derivative | Form 4 ↗ | |
| IBM | Other A | September 30, 2025 | October 1, 2025 | 1d | 346 | $282 | $98K | derivative | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| May 12, 2026 | Form 4 | 0001223690-26-000004 | 1 | published | EDGAR ↗ |
| April 1, 2026 | Form 4 | 0001223690-26-000002 | 1 | published | EDGAR ↗ |
| January 2, 2026 | Form 4 | 0001223690-26-000001 | 1 | published | EDGAR ↗ |
| October 1, 2025 | Form 4 | 0001223690-25-000004 | 1 | published | EDGAR ↗ |
Other insiders at AbbVie Inc.
- KRISHNA ARVIND Director 24 rows
- Hart Brett J Director 20 rows
- Miebach Michael President & CEO 20 rows
- Brown Marianne Catherine Director 19 rows
- COHN GARY D Director 18 rows
- Fehring Nicolas A. VP, Controller 18 rows
- KAVANAUGH JAMES J Director 18 rows
- Thomas Robert David Senior Vice President 18 rows
- LAMOREAUX NICKLE JACLYN Senior Vice President 16 rows
- Siatis Perry C EVP, GC AND SECRETARY 16 rows
Everyone on file, with contracts and lobbying under the company's name: AbbVie Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 4 | 4 | October 1, 2025 | May 12, 2026 | Form 4 list on EDGAR |
Site built November 12, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.